<?xml version="1.0" encoding="UTF-8"?>
<ref id="B102">
 <mixed-citation publication-type="journal">
  <person-group person-group-type="author">
   <name>
    <surname>Ko</surname>
    <given-names>W. C.</given-names>
   </name>
   <name>
    <surname>Rolain</surname>
    <given-names>J. M.</given-names>
   </name>
   <name>
    <surname>Lee</surname>
    <given-names>N. Y.</given-names>
   </name>
   <name>
    <surname>Chen</surname>
    <given-names>P. L.</given-names>
   </name>
   <name>
    <surname>Huang</surname>
    <given-names>C. T.</given-names>
   </name>
   <name>
    <surname>Lee</surname>
    <given-names>P. I.</given-names>
   </name>
   <etal/>
  </person-group>. (
  <year>2020</year>). 
  <article-title>Arguments in favour of remdesivir for treating SARS-CoV-2 infections</article-title>. 
  <source>Int. J. Antimicrob. Agents</source>
  <volume>55</volume>:
  <fpage>105933</fpage>. 
  <pub-id pub-id-type="doi">10.1016/j.ijantimicag.2020.105933</pub-id>
  <?supplied-pmid 32147516?>
  <pub-id pub-id-type="pmid">32147516</pub-id>
 </mixed-citation>
</ref>
